Stem cells tested as potential therapy for coronavirus in trial at University of Maryland medical school – Baltimore Sun

The remarkable clinical outcomes in these critically ill patients continue to underscore the potential benefits of remestemcel-L as an anti-inflammatory agent, said Dr. Silviu Itescu, Mesoblasts CEO, in a statement at the time. "We intend to rapidly complete the randomized, placebo-controlled Phase 2/3 trial in COVID-19 ARDS patients to rigorously confirm that remestemcel-L improves survival in these critically ill patients.

Go here to read the rest:

Stem cells tested as potential therapy for coronavirus in trial at University of Maryland medical school - Baltimore Sun